David M. Ross

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

David M. Ross, Susan Branford, John F. Seymour et al. · Blood · 2013 · 706 citations

Medicine, Immunology, Pharmacotherapy +11

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Andrew A. Wylie, Joseph Schoepfer, Wolfgang Jahnke et al. · Nature · 2017 · 596 citations

Pharmacy, Medicinal Chemistry, Pharmacology +15

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 467 citations · Full text

Medicine, Oncology, Pharmacology +9

Moving treatment-free remission into mainstream clinical practice in CML

Timothy P. Hughes, David M. Ross · Blood · 2016 · 320 citations · Full text

Medicine, Internal Medicine, Clinical Medicine +9

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

Andreas Hochhaus, Tamás Masszi, Francis J. Giles et al. · Leukemia · 2017 · 287 citations · Full text

Medicine, Hematology, Oncology +9